Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Robrecht

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
American Journal of Hematology|June 22, 2019
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)Othman Al-Sawaf, Alexandra Bazeos, Sandra Robrecht, et al.
International Journal of Cancer|September 19, 2017
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinibChristine Wolf, Angela Garding, Katharina Filarsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study GroupGabor Kovacs, Sandra Robrecht, Anna Maria Fink, et al.
Leukemia|December 21, 2018
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemiaJulia von Tresckow, Paula Cramer, Jasmin Bahlo, et al.
Blood|June 20, 2026
Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trialArmin Riecke, Sandra Robrecht, Deyan Yordanov Yosifov, et al.
Leukemia|July 14, 2019
Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLLDeyan Yordanov Yosifov, Irina Idler, Nupur Bhattacharya, et al.
Blood|September 9, 2022
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLLPaul J Hengeveld, Michèle Y van der Klift, P Martijn Kolijn, et al.
European Journal of Haematology|February 4, 2024
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemiaSibylle C Mellinghoff, Sandra Robrecht, Rosanne Sprute, et al.
The Lancet. Haematology|February 3, 2022
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Sandra Robrecht, et al.
The Lancet. Haematology|August 21, 2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trialPaula Cramer, Moritz Fürstenau, Sandra Robrecht, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
American Journal of Hematology|June 22, 2019
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)Othman Al-Sawaf, Alexandra Bazeos, Sandra Robrecht, et al.
International Journal of Cancer|September 19, 2017
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinibChristine Wolf, Angela Garding, Katharina Filarsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study GroupGabor Kovacs, Sandra Robrecht, Anna Maria Fink, et al.
Leukemia|December 21, 2018
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemiaJulia von Tresckow, Paula Cramer, Jasmin Bahlo, et al.
Blood|June 20, 2026
Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trialArmin Riecke, Sandra Robrecht, Deyan Yordanov Yosifov, et al.
Leukemia|July 14, 2019
Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLLDeyan Yordanov Yosifov, Irina Idler, Nupur Bhattacharya, et al.
Blood|September 9, 2022
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLLPaul J Hengeveld, Michèle Y van der Klift, P Martijn Kolijn, et al.
European Journal of Haematology|February 4, 2024
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemiaSibylle C Mellinghoff, Sandra Robrecht, Rosanne Sprute, et al.
The Lancet. Haematology|February 3, 2022
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Sandra Robrecht, et al.
The Lancet. Haematology|August 21, 2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trialPaula Cramer, Moritz Fürstenau, Sandra Robrecht, et al.
Pageof 6